Generic placeholder image

Recent Patents on Anti-Cancer Drug Discovery

Editor-in-Chief

ISSN (Print): 1574-8928
ISSN (Online): 2212-3970

Low Molecular Weight Heparins as Antineoplastic Agents

Author(s): Sergio Siragusa

Volume 3, Issue 3, 2008

Page: [159 - 161] Pages: 3

DOI: 10.2174/157489208786242287

Price: $65

Abstract

There is an increasing interest in the potential role of low molecular weight heparins (LMWHs) in the management of cancer patients. These antithrombotic agents have generated particular excitement because they have been proved useful in both the prevention and treatment of venous thromboembolism (VTE) in patients with malignancy. Recent reports are, at the same time, highlighting a potential role of LMWHs on patient survival due to their presumed antineoplastic action. This review will discuss the most recent reports and patents on these topics.

Keywords: Low molecular weight heparins (LMWH), antithrombotic agents, antitumor therapy, venous thromboembolism (VTE)


Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy